Screening people for serious diseases is receiving increasing attention as studies demonstrate the potential benefits of early detection and early intervention in preventing morbidity and mortality. Screening tests are available for some of the most important noncommunicable diseases, including cardiovascular disease, type 2 diabetes and several site-specific cancers. However, screening guidelines for cardiovascular disease, cancers and diabetes vary within and between countries because many national and international organizations are developing their own guidelines. There is a need to address the issue of screening for disease, with an emphasis on providing accurate and practical information relevant to all countries. This report arose from a Consultation Group meeting held at WHO headquarters in Geneva. It presents an examination of the principles of screening with an emphasis on noncommunicable disease prevention and control policy.
S creening has been defined as the systematic application of a test or enquiry to identify individuals at sufficient risk of a specific disorder to benefit from further investigation or direct preventive action, among people who have not sought medical attention because of symptoms of that disorder. 1 The World Health Organization (WHO) pioneered the development of criteria for screening 2 and these have been widely used. Many countries now have a wide variety of screening programmes available to their constituents. However, uncertainties remain in the medical and public health community about the purpose, effectiveness, pre-requisites for and proper implementation of screening programmes.
The burden of many noncommunicable diseases occurs predominantly in low-and middle-income countries. 3 Increasingly, these diseases are also occurring disproportionately in poor and disadvantaged populations in all country settings. 4 This is contributing to widening health gaps both within and between countries. It is important to ensure that screening interventions aimed at diseases in developed countries can, if appropriate, also be made available to developing countries where these conditions have already emerged as important health problems.
Even when screening is considered effective, there is often debate about how screening programmes should be managed. To implement screening programmes effectively in any country setting, rational criteria are needed to identify necessary programmes and determine how they should be managed. Such criteria are particularly important for decision makers, who are likely to be under strong pressure to introduce or maintain screening services even in the absence of adequate scientific evidence of their effectiveness or when the required health care infrastructure is lacking.
As our knowledge of noncommunicable diseases and their risk factors improves, our ability to identify, prevent and treat them is also likely to improve. Future screening policies will reflect these innovations. Nevertheless, a screening programme should be thought of as a service that incorporates all steps in the process that leads to the control of disease, including diagnosis and treatment.
This document seeks to address some of these uncertainties by defining the role of screening in the prevention and control of noncommunicable disease. We do so under the following headings:
The purpose of medical screening; Types of medical screening; Principles of medical screening; Requirements of a worthwhile screening test; Issues relating to cancer screening; Screening within the context of the health care system; Monitoring of a screening programme.
PURPOSE OF MEDICAL SCREENING
Effectively implemented medical screening can prevent disability and death and improve the quality of life. The poor prognosis for people with diseases that are diagnosed at an advanced stage can make early detection and intervention a worthwhile strategy. There are, however, two important concepts that need to be considered before initiating a screening programme: 5 The value of a screening test needs to be determined before it is introduced into practice. There is a need to quantitatively determine the levels of disability and Screening people for serious diseases is receiving increasing attention as studies demonstrate the potential benefits of early detection and early intervention in preventing morbidity and mortality. Screening tests are available for some of the most important noncommunicable diseases, including cardiovascular disease, type 2 diabetes and several site-specific cancers. However, screening guidelines for cardiovascular disease, cancers and diabetes vary within and between countries because many national and international organizations are developing their own guidelines. There is a need to address the issue of screening for disease, with an emphasis on providing accurate and practical information relevant to all countries. This report arose from a Consultation Group meeting held at WHO headquarters in Geneva. It presents an examination of the principles of screening with an emphasis on noncommunicable disease prevention and control policy.
Effectively implemented medical screening can prevent disability and death and improve the quality of life. The poor prognosis for people with diseases that are diagnosed at an advanced stage can make early detection and intervention a worthwhile strategy. There are, however, two important concepts that need to be considered before initiating a screening programme: 5 The value of a screening test needs to be determined before it is introduced into practice. There is a need to quantitatively determine the levels of disability and premature death that can be prevented by screening. The benefits can then be set against the financial costs and human costs to the screenee of anxiety, discomfort, adverse effects, follow-up investigations and treatments so that a rational decision can be made.
Early detection of disease is not an end in itself.
Screening should be concerned only with the detection of diseases or disorders that are known to cause significant suffering, disability or death if detected at a later stage. Identification of either trivial or untreatable conditions can cause anxiety and waste resources with no practical outcome.
Screening tests are usually applied on a large scale. They are used to distinguish apparently unaffected people from those who may have, or may develop, a disease. A screening test is not intended to be diagnostic. Screening procedures are generally easier to perform and cheaper than diagnostic procedures. Their results require confirmation through definitive diagnostic tests or sometimes through direct preventive treatment. Even if the screening test is harmless, it can cause anxiety and the subsequent investigations and treatment can be hazardous. Ensuring the safety of screening is also of importance because large numbers of individuals will be screened, creating a potential for greater numbers to be harmed by unsafe screening tests.
Decisions not to screen
The best preventive strategy does not always include screening. Where an important risk factor can be significantly reduced without selecting a group for preventive action (e.g. smoking), it is desirable to concentrate available resources on mass public education or other policy initiatives for this purpose.
TYPES OF MEDICAL SCREENING
Many terms used to explain medical screening are ill defined and poorly understood. Examples include opportunistic screening, case-finding, targeted screening, and genetic screening. These categorizations can lead to confusion about the purpose of screening from a population health perspective. Medical screening can be provided for an increasingly wide range of disorders and the goal is always to benefit the individuals being screened, reducing disability and the risk of death. This differs from surveillance, where the goal is to provide health information about the prevalence of specific diseases or risk factors in the population. It also differs from monitoring or occupational testing to maintain the health of employees. These have different functions and are not the focus of this document.
The term targeted screening, sometimes used to describe the process of screening a selected sub-population according to prior knowledge of which groups are at greatest risk, is confusing because the act of selecting a sub-population is itself screening: the initial questioning that defines the subpopulation is a screening activity. Opportunistic screening is sometimes used to imply the application of screening tests within routine health services without an attempt to include them in an organized programme. In effect, the term is used to describe unsystematic screening activity sometimes given to the wrong people and often of unproven value. Case finding is best avoided because confusion arises over the definition of the 'case'; case usually refers to a person with the disease in question but in case finding the case is actually a person with a positive screening test. Case finding tends to legitimize nonsystematic screening, with all the weaknesses this entails, including no specification of the expected health benefits in terms of disease prevention and little or no capability of monitoring the screening service. The following may encourage the adoption of sound screening concepts.
Focus on the specific disorder that screening is intended to prevent (that is, screening for prevention of stroke rather than screening for hypertension);
Avoid terminology that relates to the screening technology rather than the disease (that is, ultrasound screening rather than screening for neural tube defects using ultrasound); Avoid broad terms (e. g. genetic screening) because their lack of specificity makes them unclear. Instead, indicate the gene(s) for which screening is conducted (e.g. screening for breast cancer using tests for BRCA 1 and 2).
Screening tests, while generally easier to perform and less expensive than diagnostic tests, yield indefinite results, indicating a probability of having or developing the disorder in question if positive and usually requiring the subsequent application of a diagnostic test.
PRINCIPLES OF MEDICAL SCREENING
It has been pointed out that medical screening contains three elements: 1 1. It is the process of selection with the purpose of identifying those individuals who are at a sufficiently high risk of a specific disorder to warrant further investigation or sometimes direct action. It is usually a preliminary process to offering a diagnostic test and, if required, treatment; 2. It is systematically offered to a population of people who have not sought medical attention on account of symptoms of the disease for which the screening is being conducted. It is normally initiated by medical authorities and not following a patient's request for help on account of a specific complaint; 3. Its purpose is to benefit the individuals being screened.
On this basis mass testing, such as surveillance for HIV infection or pre-employment examinations to test fitness for work, would not be classified as medical screening.
An important distinction between screening and medical diagnosis and care is that the individual who is the subject of screening does not originate the encounter. Rather, screening is initiated by the health service provider. This is true whether screening is initiated by governments or public health units, or whether it is carried out by the physician in his or her office. When a patient goes to see a physician for diagnosis of and hopefully relief from a symptom, or for treatment of an established condition, the physician is required to exercise his or her skills only to the extent that knowledge is currently available. In screening, however, those who are invited to participate are not patients, and most of them do not become patients. The screener believes that as a result of screening, the health of the community will be better. This does not necessarily imply that the condition of every individual screened will be better, but in premature death that can be prevented by screening. The benefits can then be set against the financial costs and human costs to the screenee of anxiety, discomfort, adverse effects, follow-up investigations and treatments so that a rational decision can be made.
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PRINCIPLES OF MEDICAL SCREENING
An important distinction between screening and medical diagnosis and care is that the individual who is the subject of screening does not originate the encounter. Rather, screening is initiated by the health service provider. This is true whether screening is initiated by governments or public health units, or whether it is carried out by the physician in his or her office. When a patient goes to see a physician for diagnosis of and hopefully relief from a symptom, or for treatment of an established condition, the physician is required to exercise his or her skills only to the extent that knowledge is currently available. In screening, however, those who are invited to participate are not patients, and most of them do not become patients. The screener believes that as a result of screening, the health of the community will be better. This does not necessarily imply that the condition of every individual screened will be better, but in Current concepts in screening for noncommunicable disease 13 general this should be so. In screening there is an ethical responsibility to conduct programmes that will be of overall benefit to those who are screened and will minimize the harm and anxiety that will arise. It is not simply the offering of medical tests for people to accept or reject as they wish. This responsibility implies that if evidence is not available from valid studies on the effectiveness of screening, screening should not be offered. Those responsible for screening programmes also have an ethical responsibility to ensure that quality control of the screening tests is maintained and that the effectiveness of proven, beneficial programmes is monitored 6 and improved if possible.
In screening there is a duty to avoid unnecessary anxiety, recognizing that screening necessarily and legitimately creates anxiety. This requires selecting screening methods that will have the lowest proportion of false-positives without sacrificing the detection of true-positives. There is also a duty to ensure that a useful remedy is available for all individuals correctly identified as being test positive. There should be no one for whom either a definitive diagnostic test is not available or direct action cannot be offered. If this is not the case, screening will merely generate groups of anxious individuals for whom there is no benefit. In general, therefore, the process of screening should identify two groups;
Test-positives for whom further action is warranted; Test-negatives for whom no further action is warranted.
Producing an intermediate category is not useful. The intermediate group is better dichotomized to a test-positive group that requires further action, and a test-negative group that does not. Those who are test-positive usually return for diagnosis and treatment, if necessary, although sometimes they may return for another test. A screening programme must ensure that sufficient explanation is given of the implications of a positive test. Some provision should be made to ensure that test-positives have somewhere to return to for further medical advice and if necessary, counselling. A screening programme that fails to take these considerations into account is failing in its duty of care.
Equity of access to screening services is an important consideration. All those who stand to gain from screening should have access to the procedure. A screening service should not be a service that relies on individuals seeking out particular tests or procedures that they have heard may be of value. Instead, those who organize the service have an obligation to ensure that those who have not heard of the screening test but who stand to benefit from it are adequately informed and have access to screening.
A general ethical consideration is that limited resources be distributed equitably across the community to maximize health benefits. This is not an issue specific to screening. However, screening could diminish the overall level of health in a community if it resulted in fewer resources being available for other diseases. On the other hand, a well conceived and well organized screening programme will improve health overall.
REQUIREMENTS FOR SCREENING
Nine requirements for screening have been specified. Before implementing any screening activity, it is important to determine whether or not these requirements are met. These are summarised in Table 1 .
Disorder
The disorder for which screening is being carried out should be well defined. This seems self-evident but problems arise when the disorder is defined as the screening test. Using casual blood glucose levels to detect the risk of diabetes mellitus is such an example. Having a raised blood glucose level (i.e. hyperglycaemia) is not necessarily an indication of having diabetes mellitus, but indicates an increased risk of having the disorder. A specified high glucose level should be regarded as a positive test, not as the disorder being screened for. The 'gold standard' test for diabetes requires measuring blood glucose concentration either by the oral glucose tolerance test, or a fasting glucose, repeated on two separate occasions. 8 To use blood sugar to screen for hyperglycaemia creates a circular reasoning that tells us nothing about the value of measuring blood sugar to distinguish those who will develop diabetes and its complications from those who will not.
A similar circularity applies to the use of blood pressure measurements in screening to detect so-called hypertension. Hypertension is no more than high blood pressure and it is a risk factor for developing serious preventable diseases, such as coronary heart disease and stroke. There is little point in asking how well blood pressure measurement can identify high blood pressure. The real issue is how well it can distinguish people who develop a stroke or heart attack from those who do not. The issue is more than a semantic debate about clarifying terminology because only when the definition of disease is made independently of the screening test can the performance of the test be properly assessed.
Prevalence
The prevalence (or incidence) of a disorder needs to be known. Screening is likely to be acceptable only if the prevalence of the condition exceeds a certain level and once a decision to screen is made, the prevalence will determine the screening policies since the chance of being affected given a positive screening test depends on the prevalence of the disorder in the population. Data on the prevalence and incidence of noncommunicable diseases are likely to vary from country to country. Most developed countries have cancer registries and in some countries notification of certain types of cancers is a legal requirement. Prevalence and incidence data for other diseases can be hard to obtain and extrapolations for a whole country may have to be made on the basis of epidemiological survey information or ad hoc studies designed to estimate prevalence. general this should be so. In screening there is an ethical responsibility to conduct programmes that will be of overall benefit to those who are screened and will minimize the harm and anxiety that will arise. It is not simply the offering of medical tests for people to accept or reject as they wish. This responsibility implies that if evidence is not available from valid studies on the effectiveness of screening, screening should not be offered. Those responsible for screening programmes also have an ethical responsibility to ensure that quality control of the screening tests is maintained and that the effectiveness of proven, beneficial programmes is monitored 6 and improved if possible.
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Prevalence
The prevalence (or incidence) of a disorder needs to be known. Screening is likely to be acceptable only if the prevalence of the condition exceeds a certain level and once a decision to screen is made, the prevalence will determine the screening policies since the chance of being affected given a positive screening test depends on the prevalence of the disorder in the population. Data on the prevalence and incidence of noncommunicable diseases are likely to vary from country to country. Most developed countries have cancer registries and in some countries notification of certain types of cancers is a legal requirement. Prevalence and incidence data for other diseases can be hard to obtain and extrapolations for a whole country may have to be made on the basis of epidemiological survey information or ad hoc studies designed to estimate prevalence. 
Natural history
In screening, priority should be given to disorders that have a significant impact on the quality of life and survival of a large proportion of the population. Preventive measures or treatments have to be available which are more effective at the screen-detected stage than interventions applied after clinical presentation. For this to be known, it is necessary to know the natural history of the disorder and the efficacy of actions that follow a positive screening test (including efficacy of the treatment or preventive action) compared with what would occur in the absence of screening. This should be known before screening programmes are implemented.
Adequate facilities and trained staff must exist for formal diagnosis, treatment and follow up of newly diagnosed cases, which could otherwise overwhelm the health services.
The screening test
The screening test of choice should be safe and simple. The use of invasive tests with risks that outweigh the potential benefits should be avoided. The tests should be offered in a way that respects people's concerns, their right to make choices, and their privacy and confidentiality. If there is no safe and ethical method of screening and timely intervention, the possibility of using screening should be rejected and alternative approaches should be developed to address the problem.
Screening test performance
One of the aims of this paper is to clarify the different uses of screening terms, and in doing so to facilitate a better understanding of the concepts involved in evaluating screening tests. Tables 2a and b give the main terms used in screening for noncommunicable diseases. The process of screening and diagnosis results in the identification of only two of the cells in Table 2a , those identified as 'a' (the true positives) and 'b' (the false positives). In particular, 'c' (the false negatives) are not known at the time, and can only be identified by the systematic and uniform follow-up of all people screened. This is not always possible, particularly in cancer screening, so sometimes 'c' cannot be determined. If 'c' can be determined, 'd' can be calculated by subtraction.
The terms detection rate (DR) and sensitivity are frequently used as synonyms. Both terms define the proportion of individuals with the disorder who test positive divided by all those with the disorder. However, DR has a different meaning in cancer screening. In this context, it is the number of screen positive individuals found in the population of individuals screened. To avoid confusing cancer terminology with that of the broader spectrum of noncommunicable disease screening, this use of DR is better described as the 'prevalence of screen-positive cancers in the screened population'.
False positive rate (FPR), or the proportion of unaffected individuals with positive tests, is the complement of specificity. Specificity is the proportion of individuals without the disorder who correctly test negative. Even though not all individuals with disease can be determined by the screening process alone, as indicated above, the proportion of false negatives among those who test negative is usually so low that the specificity (d/d þ b) can be approximated by the proportion
Proposals that the terms DR and FPR should substitute for sensitivity and specificity have arisen because:
Sensitivity has a different meaning in the context of screening and biochemistry, where it means the minimum detectable concentration. This can be confusing, particularly when screening involves biochemical testing;
The term false positive focuses attention on the group that will be offered medical intervention, not the group that will not;
Changes in the FPR are easier to interpret quantitatively than the same change in specificity. For example, a 10% FPR results in twice the number of unaffected people being offered intervention compared with a 5% FPR, whereas the corresponding change in specificity from 95% to 90% makes this difference less obvious.
As indicated, determining the DR (sensitivity) is straightforward when all individuals can be found to be either affected or unaffected. In cancer screening this may not be possible because if a lesion is found and a treatment carried out, one cannot know if that lesion would have become a clinical case had treatment not been given. The problem arises for any progressive disorder in which the clinical outcome is not determined in a uniform way among all individuals as would be the case if all screening research was initially observational without intervention regardless of the result of the screening test. Sometimes such an observational approach is possible, for example by storing serum samples in a population of adults (without testing them at the time of collection), following up the individuals, and later identifying those with and without the cancer of interest. Then the serum samples can be retrieved from storage and tested on a case-control basis. This provides an unbiased estimate of the screening performance of the proposed blood test. Such an approach, however, is not practical with tests based on imaging, for example a mammogram in breast cancer screening, since the X-rays could not simply be taken and stored without being 
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As indicated, determining the DR (sensitivity) is straightforward when all individuals can be found to be either affected or unaffected. In cancer screening this may not be possible because if a lesion is found and a treatment carried out, one cannot know if that lesion would have become a clinical case had treatment not been given. The problem arises for any progressive disorder in which the clinical outcome is not determined in a uniform way among all individuals as would be the case if all screening research was initially observational without intervention regardless of the result of the screening test. Sometimes such an observational approach is possible, for example by storing serum samples in a population of adults (without testing them at the time of collection), following up the individuals, and later identifying those with and without the cancer of interest. Then the serum samples can be retrieved from storage and tested on a case-control basis. This provides an unbiased estimate of the screening performance of the proposed blood test. Such an approach, however, is not practical with tests based on imaging, for example a mammogram in breast cancer screening, since the X-rays could not simply be taken and stored without being examined at the time. If a lesion were seen there would be an ethical obligation to perform a biopsy and, if necessary, treatment. The problem with not being able to obtain an estimate of the DR for disorders such as cancer is not principally because the condition is a progressive one but because the nature of the screening test may not allow the initial evaluation of the screening test to be performed on an observational basis. In such circumstances, it may never be possible to know the screening performance of the test. The solution is to perform a randomized trial of screening followed by treatment to determine whether such a strategy reduces mortality from the disease in question. If it does, we know the combined effect of the screening test and treatment but may not be able to partition the relative contributions of the two in a achieving the health benefit.
Test performance
The DR (or sensitivity) and the FPR (or specificity) are the two main measures of test performance. They answer the questions:
To what extent can the test distinguish affected from unaffected individuals?
What is the chance that those who have positive results are affected?
For a qualitative test (one that naturally falls into a positive or negative category), the DR and FPR are defined by the relevant cells in Table 2a . For such tests, the DR and FPR are fixed. For a quantitative test such as blood pressure, where the results are distributed as a continuous variable, they are obtained from knowing the separate relative frequency distributions of test values for both affected and unaffected individuals. The DR and FPR are then determined at different cut-off levels, from which the data Table  2a can be derived. The odds of being affected given a positive result (OAPR) can be calculated from the DR, the FPR, and the prevalence expressed as an odds ratio so that:
OAPR ¼ DR=FPR Â prevalence as an odds ratio The positive predictive value (PPV) is the OAPR as a probability, so, for example, an OAPR of 1:3 is the same as a PPV of one quarter or 25%. Sometimes only screen-positives are followed up and then an OAPR can be determined without knowledge of the DR or FPR; for example, if one woman out of every three women with a positive mammogram who have a biopsy has breast cancer, and two do not, the OAPR is 1:2 (PVP 33%). The DR/FPR is generally known as the likelihood ratio. This is a critical parameter that determines the value of a screening test.
A graphical plot (called an ROC or 'receiver operator curve') of the DR against the FPR is a convenient and useful way of showing the trade-off between the DR and the FPR for a given screening test and can be useful in determining an appropriate cut-off level.
Financial considerations
Screening should be cost-effective; that is, it should maximize efficacy for a given cost. When this also maximizes the DR for a given FPR there is no conflict between medical and financial considerations. Sometimes the best screening policy from a medical perspective is not the most cost-effective financially. A judgment is then needed on whether the extra cost justifies the health gain.
The costs and benefits of screening and intervention activities must always be weighed against those of alternative strategies. In general, interventions that eliminate the causes of disease should have priority over approaches involving health screening that seeks to minimize the health damage of exposures. A population approach correcting or reversing adverse risk factors may be more effective.
Facilities for screening programmes
In order to determine the requirements for a programme, it is necessary to evaluate the political commitment for funding and to estimate the total resources and costs involved in screening, diagnosis and effective intervention. It is not generally appropriate to implement screening until provision for diagnosis and long-term follow-up for those in greatest need can be assured. This is particularly important when screening for noncommunicable diseases, as treatment may be lifelong and entail substantial resources.
Acceptability of screening programme
Even if the screening test fulfils the criteria mentioned above, it is essential to question whether an ethical, acceptable, safe and effective intervention is possible. Diagnostic and therapeutic interventions that result in social stigmatisation or offend cultural norms, or ones that are inconvenient or invasive, are unlikely to be accepted by the public. Even services that are ethical, acceptable and safe may not be used if the population does not value them.
Equity
In considering this criterion, it is helpful to ask whether screening, diagnosis and intervention will increase equity in the allocation of health resources, improve health status for those in greatest need and strengthen the infrastructure of the local health system. When the infrastructure for basic preventive and curative services is inadequate to cover the entire population, screening activities tend to increase inequities in the distribution of resources for health and may retard long-term social development. Alternative approaches that do not involve screening, typically those directed at primary prevention and at providing universal access to basic services, may be preferable.
ISSUES RELATING TO CANCER SCREENING Problems of using survival as a measure of screening efficacy
A number of issues have to be considered when evaluating the success of cancer screening programmes. Individuals with cancer identified as a result of screening will, on average, have a longer survival time than those diagnosed in the normal way. This is lead-time, defined as the interval between the time of detection by screening and the time at which the disease would have been diagnosed in the absence of screening. It is the period by which screening advances the diagnosis of disease. Lead-time has two components; one arises simply because the date of diagnosis is earlier than the date of diagnosis following clinical presentation without altering the date of death from the cancer. This is lead-time bias. The other component is due to increasing the interval by prolonging life. This is lead-time gain. 
Facilities for screening programmes
In order to determine the requirements for a programme, it is necessary to evaluate the political commitment for funding and to estimate the total resources and costs involved in screening, diagnosis and effective intervention.
It is not generally appropriate to implement screening until provision for diagnosis and long-term follow-up for those in greatest need can be assured. This is particularly important when screening for noncommunicable diseases, as treat-ment may be lifelong and entail substantial resources.
Acceptability of screening programme
Even if the screening test fulfils the criteria mentioned above, it is essential to question whether an ethical, acceptable, safe and effective intervention is possible. Lead times will vary depending on the timing of the screening test in relation to the duration of the asymptomatic phase and the rapidity of disease progression. 9 The determination of lead time is complex, but models to compute it are available providing there are control data that permit comparison of screen detected cases with what would be expected in the general population. 10 The second bias that accounts for improved survival of screen-detected cases is length-biased sampling. This arises from individuals who have rapidly progressive disease tending to develop symptoms soon after the initiation of the cancer that cause them to consult physicians directly. Thus only less rapidly progressive cases are likely to remain to be detected by screening. The former have a poorer prognosis than the latter, hence the improved survival of screen-detected cases over and above lead-time. This bias is most obvious at the initiation of a screening programme, at the first or prevalent screening examination. However, length-bias will also affect the type of cases detected at rescreening, with more rapidly progressive diseases detected in the interval between screens. Thus interval cases as well as the screen-detected cases must be identified and taken into consideration in evaluating the total impact of the programmes. The best way of avoiding the effect of lead-time bias and length-biased sampling is to use mortality rates from the cancer, ie, deaths from the cancer per 1000 screened, regardless of the interval between detection and death.
Selection bias
Selection bias can lead to incorrect estimates of the effect of screening. Those who enter screening programmes are volunteers and, for example, may be of higher socioeconomic status and more health conscious than those who decline to enter. This means that they are likely, even in the absence of screening, to have a different outcome from their disease than the overall rates in the general population. With cervical cancer the bias will tend to make screening look more favourable than it is, but for breast cancer it will have the opposite effect.
Selection bias can be overcome by means of a randomised controlled trial so that death rates in screened and unscreened groups are compared instead of survival.
A randomised controlled trial evaluating screening can be based on randomisation of the screening test, which answers the biologically relevant question of whether or not mortality is reduced in those screened. Alternatively, it can be based on the randomisation of invitations to attend for screening, so both those who accept the invitation and those who refuse are included in the assessment of outcome. Thus it tests the impact of introducing screening in a population. Some trials of this type involve randomisation of doctors' practices or counties -so called cluster randomisation.
If for some reason randomisation is believed inappropriate, there are alternative approaches but all have shortcomings. Similarly, mortality from the disease in defined populations before and after the introduction of screening programmes can be compared for a case control study used to evaluate programmes that were introduced sufficiently long before the study that an effect could be expected to have occurred. Case control studies depend on comparing the screen histories of the cases with the histories of comparable controls drawn from the population from which the cases arose. 11 Selection bias remains a concern in interpreting the results.
Similarly, death rates from the cancer that is being screened for can be compared with expected death rates in unscreened people. In these studies, it has to be recognized that those recruited into a screening programme are initially free of the disease of interest, so it may not be appropriate to apply population mortality rates for the disease to the person-years experience of the study cohort. Rather, it is first necessary to determine the expected incidence of the disease of interest, and then apply the expected case-fatality rate from the disease to that expectation to derive the expectation for the deaths. In practice, a cohort study of screening suffers from the same problem of selection bias as case control studies, so the results have to be interpreted with caution.
Indirect measures of screening efficacy
A useful measure of cancer screening efficacy is the shift in the stage distribution of cases detected by screening compared with clinically detected cases. A large shift towards less advanced cases indicates efficacy. A reduced prevalence of cancer at screening examinations after the first screen is also an indicator of efficacy.
The proportional interval cancer incidence is the incidence of cancer after a negative screening examination divided by the incidence in the absence of screening. If this is low, say 0.2 in the first year after breast cancer screening, it is an indicator of efficacy. As it approaches 1.0, the effect of screening is becoming lost.
These are all useful monitoring measures in established screening programmes.
Screening intervals
Determining the frequency of screening is helped by knowledge about the natural history of the condition to be screened for, including the duration of the asymptomatic (latent) phase. Frequent screening will result in a low number of cases per screen and thus a low predictive value. The reason for this outcome is that relatively few new cases in the asymptomatic disease phase will have a chance to develop over a short interval. On the other hand, infrequent screening will leave the disease uncontrolled. 12 Screening programmes seek to maximize the reduction in incidence of and mortality from a disease given available resources. The appropriate screening interval is one that provides a favourable ratio between the degree of disease control and the cost of screening. Models can facilitate decisions on the optimal periodicity of screening. An example is an analysis done to provide guidance on breast screening. 13 
SCREENING WITHIN THE HEALTH CARE SYSTEM Screening in a health care context
Screening programmes should be integrated within the existing health system or within the infrastructure of communities, for example, by having screening units in shopping centres.
Screening in a local context
There is a tendency to favour screening programmes simply because such programmes have been implemented in exemplar countries (e.g. the US or UK). 14 Lead times will vary depending on the timing of the screening test in relation to the duration of the asymptomatic phase and the rapidity of disease progression. 9 The determination of lead time is complex, but models to compute it are available providing there are control data that permit comparison of screen detected cases with what would be expected in the general population. 10 The second bias that accounts for improved survival of screen-detected cases is length-biased sampling. This arises from individuals who have rapidly progressive disease tending to develop symptoms soon after the initiation of the cancer that cause them to consult physicians directly. Thus only less rapidly progressive cases are likely to remain to be detected by screening. The former have a poorer prognosis than the latter, hence the improved survival of screen-detected cases over and above lead-time. This bias is most obvious at the initiation of a screening programme, at the first or prevalent screening examination. However, length-bias will also affect the type of cases detected at rescreening, with more rapidly progressive diseases detected in the interval between screens. Thus interval cases as well as the screen-detected cases must be identified and taken into consideration in evaluating the total impact of the programmes. The best way of avoiding the effect of lead-time bias and length-biased sampling is to use mortality rates from the cancer, ie, deaths from the cancer per 1000 screened, regardless of the interval between detection and death.
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Screening in a local context
There is a tendency to favour screening programmes simply because such programmes have been implemented in exemplar countries (e.g. the US or UK). 14 Such pressures can conflict with the need to assess the value of a Current concepts in screening for noncommunicable disease 17 comprehensive analysis of a screening programme on objective scientific criteria, including the acceptability and practicality of screening in local settings. The objectives of the programme need to be considered carefully before implementation. The objectives of a screening programme can compete with other health care priorities. On the one hand a programme must reduce serious morbidity and mortality from a specific disease. On the other hand, the costs of screening must not be allowed to escalate to the detriment of other useful health services.
The role of primary care
In many countries, a high proportion of the population has contact with primary care for their health needs. However, primary care in this context is often concerned with dealing with individual problems, and primary care practitioners often have insufficient time available to offer preventive or screening services. If primary care is to be used as a focus for screening, sufficient resources will have to be made available for this purpose.
Primary health care has an important role in the primary and secondary prevention of noncommunicable diseases. Integrating secondary prevention interventions, including early detection, into primary care is one of the major strategies to upgrade health care and improve outcomes. At this level of health care, screening for specific conditions can be a potentially useful tool in identifying those in greatest need of particular interventions to promote health or prevent disease.
Primary health care centres have a major role in public health education and early detection and screening; medical, paramedical, and community care workers should be the resource people for these activities and a major and effective link in the referral chain of screen-positive individuals to diagnostic and treatment centres.
To ensure effectiveness and to promote equity -one of the principles of primary health care -screening should be population-based (i.e. focused on populations and subpopulations known to be at the greatest risk of having the particular health problem that is being sought and in greatest need of the measures available to address it). With such a population-based approach, priority would be given to outreach activities directed at high-risk sub-populations. 15 Primary health care teams, particularly in developing countries, are under staffed and have a heavy service load. A category of paramedical staff, such as practice nurses, may have to be recruited into primary health care services to facilitate screening programmes. In some countries practice nurses are already making a major contribution to screening and health promotion services.
Infrastructure needs
Appropriate data collection and maintenance of data are necessary to ensure the continued progress of the screening programme. A population-based information system is the basic building block of organized screening programmes (see below). Such information systems must be capable of supporting several objectives including individual information retrieval and sophisticated aggregated and comparative data analyses. An example of the requirements for an information system for cervical cancer screening programmes can be found in Miller. 16 The development of information systems will be facilitated by the introduction of permanent individual health care identifiers. However, the establishment of databases to support screening programmes need not be dependent upon unique individual identifiers and should not be delayed where such identifiers are not yet in use.
THE COMPONENTS OF AN ORGANIZED SCREEN-ING PROGRAMME
A national framework for implementation with welldefined aims and standards is a prerequisite for an effective screening programme. 6 The components of an organized screening programme include the following:
A clear definition of the objectives of the programme, and the expected health benefits;
The individuals in the population who stand to benefit from screening are identifiable;
Measures are available to encourage high coverage and attendance (e.g. health education, a personal letter of invitation and reminders where possible);
Adequate resources to register health information to be used for evaluation and monitoring of the programme;
Adequate facilities are available for having the tests and interpreting them;
There is an organized quality control programme for both the screening tests and for their interpretation;
Adequate facilities exist for diagnosis and appropriate treatment;
A referral system exists for management of any abnormalities found and for providing information about normal screening tests;
Programme data are maintained so that evaluation and monitoring of the programme can be done regularly.
MONITORING A SCREENING PROGRAMME
Once an organized screening programme has been implemented, it is important to remain vigilant in the evaluation and monitoring of the programme. The collection and analysis of programme data on an on-going and periodic basis are key factors in ensuring that the programme meets high standards of care. The programme must consider its original objectives and develop indicators that allow for monitoring and evaluating these objectives in an unbiased manner. These indicators are the building blocks for a successful evaluation initiative and depend on accurate and reliable data that are consistent and timely.
Effective population-based screening programmes usually require uptake by a significant proportion of individuals in the target population, if necessary an appropriate screening interval, a high quality screening test and successful referral to clinical follow-up to the point of diagnosis. The following checklist may be helpful:
Purpose of screening; Prevalence of disease in the population screened; Uptake among those invited; Sensitivity (DR); FPR; The odds of being affected given a positive screening result;
Disease-specific mortality. comprehensive analysis of a screening programme on objective scientific criteria, including the acceptability and practicality of screening in local settings. The objectives of the programme need to be considered carefully before implementation. The objectives of a screening programme can compete with other health care priorities. On the one hand a programme must reduce serious morbidity and mortality from a specific disease. On the other hand, the costs of screening must not be allowed to escalate to the detriment of other useful health services.
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Programme features, such as the acceptability of the programme to the target group, the functioning of the referral system and compliance with it and facilities for diagnosis and treatment in the health service will to some extent be reflected in the above-mentioned indicators. Other features, such as cost per case detected, may change over time as the programme matures. Programme objectives will also change over time. The evaluation process should take this into consideration by providing a method for updating the indicators of programme performance.
Indirect indicators of effectiveness are often desired in evaluating screening programmes, especially indicators that predict subsequent mortality. Compliance with screening, the proportion of cases detected by screening, and the ratio of prevalence and incidence can be indicators of potentially effective screens. The prevalence of advanced disease is another such measure. However, case detection frequency and stage shift in percentages of the total should not be used as indicators of effectiveness as they potentially reflect all four screening survival biases.
In general, indicators used to evaluate screening programmes are indirect measures of the programme's success. Examples of such measures include whether or not the programme is effective in reducing disease-specific morbidity and mortality in the general population. Morbidity is often measured as the number of new cases of a disease in the population at a specific point in time (i.e. incidence). Paradoxically, the introduction of a screening programme may result in an increase in the incidence of the disease in the short term. This results directly from the early detection of cases in individuals without symptoms who may otherwise go undetected for a number of years. Examining incidence over time will eventually provide a picture of the impact of screening on the disease in the community being screened.
Disease-specific mortality rates are an important indication of the effectiveness of a screening programme. Change in disease-specific mortality rates over time in the target population for screening is perhaps the most important measure of the efficacy of a screening programme for a disease that is usually fatal, but changes in disease-specific mortality rates may not be apparent for a number of years following the commencement of a screening programme. Accordingly, this measure needs to be viewed over the longer term.
Screening programmes should invest effort in the development of a monitoring plan. The plan should focus on the key outcome measures. As well as monitoring rates of the disease that screening is designed to control, programme indications of effectiveness should be identified and systematically monitored to ensure that the programme remains useful over time.
Considered as a public health prevention programme, screening has much to offer provided it is based on sound research and good practice, and all reasonable steps are taken to ensure that it is implemented in a manner that is as effective and safe as possible. Programme features, such as the acceptability of the programme to the target group, the functioning of the referral system and compliance with it and facilities for diagnosis and treatment in the health service will to some extent be reflected in the above-mentioned indicators. Other features, such as cost per case detected, may change over time as the programme matures. Programme objectives will also change over time. The evaluation process should take this into consideration by providing a method for updating the indicators of programme performance.
Considered as a public health prevention programme, screening has much to offer provided it is based on sound research and good practice, and all reasonable steps are taken to ensure that it is implemented in a manner that is as effective and safe as possible.
